Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Voyager Therapeutics, Inc. (VYGR)
Price$3.42Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M | $171.1M | $104.4M | $7.6M | $10.1M | $14.2M | $17.3M | — |
| Research & development | $134.7M | $127.4M | $92.2M | $60.8M | $73.8M | $108.8M | $119.7M | $64.9M | $62.3M | $42.2M | $27.7M | $8.9M |
| Operating expenses | $172.2M | $163.3M | $128.0M | $91.7M | $111.0M | $143.7M | $156.1M | $98.7M | $82.0M | $55.5M | $37.6M | $14.4M |
| Operating income | −$131.8M | −$83.3M | $122.0M | −$50.8M | −$73.6M | $27.4M | −$51.7M | −$91.1M | −$71.9M | −$41.3M | −$20.3M | −$14.4M |
| Operating margin | −326.56% | −104.11% | 48.80% | −124.27% | −196.76% | 16.00% | −49.51% | −1,195.63% | −709.06% | −290.43% | −116.85% | — |
| EBITDA | −$127.8M | −$78.6M | $126.5M | −$44.6M | −$68.5M | $31.2M | −$48.9M | −$89.0M | −$70.3M | −$40.7M | −$19.7M | −$14.2M |
| EBITDA margin | −316.50% | −98.19% | 50.58% | −109.14% | −182.96% | 18.23% | −46.86% | −1,167.84% | −693.32% | −286.13% | −113.38% | — |
| Net income | −$119.7M | −$65.0M | $132.3M | −$46.4M | −$71.2M | $36.7M | −$43.6M | −$88.3M | −$70.7M | −$40.2M | −$29.7M | −$16.3M |
| Net profit margin | −296.53% | −81.25% | 52.93% | −113.45% | −190.29% | 21.47% | −41.76% | −1,158.79% | −697.56% | −282.65% | −171.18% | — |
| Basic EPSper basic share | -$2.04 | -$1.13 | $3.08 | -$1.21 | -$1.89 | $0.99 | -$1.21 | -$2.75 | -$2.64 | -$1.59 | $9.14 | $27.83 |
| Diluted EPSper diluted share | -$2.04 | -$1.13 | $2.97 | -$1.21 | -$1.89 | $0.98 | -$1.21 | -$2.75 | -$2.64 | -$1.59 | $9.14 | $27.83 |
Owners
Reported shareholders
8.44%of listed shares
BlackRock, Inc.5.17M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.44%5.17M shares |
MILLENNIUM MANAGEMENT LLC | 7.25%4.44M shares |
ARMISTICE CAPITAL, LLC | 5.61%3.44M shares |
Vestal Point Capital, LP | 4.28%2.63M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.83%2.35M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.17%1.33M shares |
Opaleye Management Inc. | 1.93%1.19M shares |
STATE STREET CORP | 1.76%1.08M shares |
TWO SIGMA INVESTMENTS, LP | 1.55%948.52K shares |
DIMENSIONAL FUND ADVISORS LP | 1.37%838.18K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.32%810.09K shares |
CITADEL ADVISORS LLC | 1.28%784.07K shares |
MORGAN STANLEY | 1.14%697.33K shares |
Erste Asset Management GmbH | 1.04%638.9K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.81%495.24K shares |
Sandrock Alfred | ≈0.77%472.55K shares |
ACADIAN ASSET MANAGEMENT LLC | 0.70%428.67K shares |
SPHERA FUNDS MANAGEMENT LTD. | 0.70%427.55K shares |
DIADEMA PARTNERS LP | 0.68%413.64K shares |
NORTHERN TRUST CORP | 0.67%411.8K shares |
Percentages use 61.27M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 2, 2026Form 4 · 10b5-1 | Sandrock AlfredPresident and CEO | SellCommon Stock | 11.5K | $3.87 | $44.5K | 472.5K |
| Feb 24, 2026Form 4 · 10b5-1 | Swartz RobinCOO & CBO | SellCommon Stock | 6.5K | $3.77 | $24.3K | 199.7K |
| Feb 24, 2026Form 4 · 10b5-1 | Sandrock AlfredPresident and CEO | SellCommon Stock | 14.2K | $3.79 | $53.8K | 484.1K |
| Feb 24, 2026Form 4 · 10b5-1 | Jorgensen Nathan D.Chief Financial Officer | SellCommon Stock | 4.7K | $3.77 | $17.6K | 151.4K |
| Feb 24, 2026Form 4 · 10b5-1 | Carter Todd AlfredChief Scientific Officer | SellCommon Stock | 4.2K | $3.76 | $15.7K | 145.7K |